# Alligator Bioscience > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/alligatorbioscience). ## Overview Alligator Bioscience is a Swedish biotech company focused on developing innovative antibody-based medicines for cancer immunotherapy. The company specializes in tumor-directed immunotherapies, leveraging its expertise in the CD40 field and antibody engineering technologies. Alligator aims to advance its drug candidates to Phase 2 clinical studies, making them attractive for out-licensing to Big Pharma for further development and commercialization. The company operates primarily from its headquarters in Lund, Sweden, and collaborates with Contract Development and Manufacturing Organizations (CDMOs) for production. ## Products & services • Tumor-directed immunotherapies • Antibody engineering technologies • CD40-focused drug candidates • Licensing and collaboration agreements • Preclinical and clinical development services - **Immunotherapies** (50%) — Includes tumor-directed therapies providing long-lasting immunity - **Antibody Engineering** (20%) — Technologies for developing unique antibody-based treatments - **Licensing Agreements** (30%) — Out-licensing of drug candidates to Big Pharma - Tumor-directed immunotherapies - Antibody engineering technologies - CD40-focused drug candidates - Licensing and collaboration agreements - Preclinical and clinical development services ## Customers Alligator Bioscience primarily targets large pharmaceutical companies interested in licensing innovative cancer immunotherapies. These partners are typically involved in the later stages of clinical development and commercialization. The company's drug candidates are designed to be attractive to Big Pharma due to their unique properties and potential for combination therapies. Alligator also collaborates with research institutions and biotech firms for early-stage development and technology sharing. - **Pharmaceutical Companies** (primary) — License drug candidates for late-stage development - **Biotech Firms** (secondary) — Collaborate on early-stage development and technology - **Research Institutions** (emerging) — Engage in joint research on cancer immunotherapy - Large pharmaceutical companies seeking innovative cancer treatments - Biotech firms interested in collaboration and technology sharing - Research institutions focused on cancer immunotherapy - Partners for late-stage clinical development and commercialization ## Geography Alligator Bioscience is headquartered in Lund, Sweden, and operates primarily within the European market. The company collaborates with international partners for clinical development and commercialization. Manufacturing is outsourced to Contract Development and Manufacturing Organizations (CDMOs) to leverage specialized expertise. Alligator's geographic focus allows it to maintain strong ties with European research institutions and biotech firms. - Headquartered in Lund, Sweden - Operates primarily within the European market - Collaborates with international partners for clinical development - Outsources manufacturing to CDMOs for specialized expertise ## Strategy Alligator Bioscience's strategic priorities include advancing its lead asset, mitazalimab, through clinical proof-of-concept in Phase 2 studies. The company focuses on out-licensing drug candidates to Big Pharma for further development and commercialization. Alligator aims to leverage its unique antibody engineering technologies to create differentiated therapies. Strategic partnerships and collaborations are key to expanding its pipeline and market reach. - **Advance mitazalimab** (medium-term) — To achieve clinical proof-of-concept - **Out-license drug candidates** (short-term) — For further development by Big Pharma - **Leverage antibody technologies** (long-term) — To create differentiated therapies - Advance mitazalimab to clinical proof-of-concept in Phase 2 - Out-license drug candidates to Big Pharma - Leverage unique antibody engineering technologies - Form strategic partnerships to expand pipeline ## Risks Alligator Bioscience faces several risks, including the uncertainty of clinical trial outcomes and reliance on partners for commercialization. The competitive landscape in immuno-oncology is intense, with rapid technological advancements. Financial risks include irregular cash flow from licensing agreements and the need for continuous funding. Geopolitical conflicts and market acceptance of new therapies also pose challenges. - **Clinical trial uncertainty** [critical] — Outcomes are unpredictable - **Reliance on partners** [high] — For commercialization and development - **Intense competition** [high] — Rapid technological advancements - **Irregular cash flow** [medium] — Dependent on licensing events - Uncertainty of clinical trial outcomes - Reliance on partners for commercialization - Intense competition in immuno-oncology - Irregular cash flow from licensing agreements - Geopolitical conflicts affecting costs - Market acceptance of new therapies ## Accounting Alligator Bioscience's financial statements are prepared in accordance with IFRS, with key accounting matters including revenue recognition from licensing agreements and impairment testing of intangible assets. The timing of milestone payments and sales-based royalties can significantly impact reported revenue. Regular impairment tests are conducted on intangible assets to ensure accurate valuation. The company's financial results are also influenced by currency fluctuations, given its international operations. - **Revenue recognition** — Significant on reported revenue - **Impairment testing** — Critical for asset valuation - **Currency fluctuations** — Influences financial results - Revenue recognition from licensing agreements - Timing of milestone payments and royalties - Impairment testing of intangible assets - Impact of currency fluctuations on financial results --- *Last updated: 2026-08-11T04:04:50.819498+00:00*